TY - JOUR
T1 - Clarithromycin use and risk of death in patients with ischemic heart disease
AU - Andersen, Søren Skøtt
AU - Hansen, Morten Lock
AU - Norgaard, Mette Lykke
AU - Folke, Fredrik
AU - Fosbøl, Emil Loldrup
AU - Abildstrøm, Steen Z
AU - Raunsø, Jakob
AU - Madsen, Mette
AU - Køber, Lars
AU - Gislason, Gunnar H
AU - Torp-Pedersen, Christian
AU - Andersen, Søren Skøtt
AU - Hansen, Morten Lock
AU - Norgaard, Mette Lykke
AU - Folke, Fredrik
AU - Fosbøl, Emil Loldrup
AU - Abildstrøm, Steen Z
AU - Raunsø, Jakob
AU - Madsen, Mette
AU - Køber, Lars
AU - Gislason, Gunnar H
AU - Torp-Pedersen, Christian
N1 - Copyright © 2010 S. Karger AG, Basel.
PY - 2010/7/1
Y1 - 2010/7/1
N2 - Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.
AB - Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.
U2 - 10.1159/000315394
DO - 10.1159/000315394
M3 - Journal article
VL - 116
SP - 89
EP - 97
JO - Cardiologia
JF - Cardiologia
SN - 0008-6312
IS - 2
ER -